Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

J&J Touts its Pharma R&D Efforts for China

publication date: May 24, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Janssen Pharmaceutical Companies, a division of Johnson & Johnson, did something this week that big pharmas haven't done very often in the last few years: it bragged about its recent drug discovery success and made predictions about its future progress. The company said it had four new medical entities awaiting approval in China along with four line extensions. It expects to file an additional nine NMEs and six line extensions for approval by 2017. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners